DCN: 19-002944 v.3.0



100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date: 7-Apr-2020		7-Apr-2023	: Date of Next Review
Prepared By: Kyle Snyder		19-002944 v.2.0	: Supersedes
QA/QC Approval: Carissa McCollian		Hannah Bernier	: Management Approval
Reason for Revision: See Revision History in	ensur.		

## **CERTIFICATE OF ANALYSIS**

## **URACIL**

## BIO PHARMA GRADE / UC4202-K001

LOT: UC4202-010-0221

C<sub>4</sub>H<sub>4</sub>N<sub>2</sub>O<sub>2</sub> ^ F.W. 112.09 g/mol. ^ CAS# 66-22-8 Manufacturing Date: 1/27/21 Retest Date: 1/31/24 Manufacturing Site: 100 Majestic Way, Bangor PA, 18013

Packaging Date: 2/25/21 Packaging Site: 100 Majestic Way, Bangor PA, 18013

Anai	LYSIS	SPECIFICATION	TEST RESULT
Appearance and C	olor	White to Slightly Yellow Powder	White to Slightly Yellow Powder
Assay		97.0-102.0%	98.6 %
Identification (IR)		Passes Test	Passes Test
Reaction		Passes Test	Passes Test
Solubility		Passes Test	Passes Test
TAMC	Alert Limit	100 CFU/g max.	<100 CFU/g
	Release Limit	1000 CFU/g max.	<100 CFU/g

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: 16-001314

<u>INTENDED USE:</u> Material represented by this Certificate of Analysis is suitable for use as a GMP process chemical. It is manufactured in accordance with the IPEC-PQG Joint Good Manufacturing Practice Guide. The material represented by this Certificate of Analysis is not suitable to be used as an Active Pharmaceutical Ingredient, Drug, Drug Product or Household Item.

Prepared by: Javan Heigher Date: 2/25/21 Job Title: QA Specialist

Reviewed by: Date: 2/25/21 Job Title: QA Supervisor